Photo by mhellmark from unsplash
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine Paronychia and pseudopyogenic granuloma (pseudo-PG) are relatively common and difficult-to-manage adverse effects… Click to show full abstract
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine Paronychia and pseudopyogenic granuloma (pseudo-PG) are relatively common and difficult-to-manage adverse effects in patients undergoing treatment with epidermal growth factor receptor inhibitors and capecitabine.1 Recently, Piraccini et al2 reported the successful treatment of chemotherapy-induced fingernail PGs with topical propranolol, 1%, cream. The aim of this study was to evaluate the efficacy and tolerability of topical timolol, 0.5%, gel as a treatment of paronychia and pseudo-PG induced by antineoplastic agents.
Journal Title: JAMA Dermatology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!